Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531
<b>Purpose:</b> We aimed to develop a simple nomogram and online calculator that can identify the optimal subpopulation of pediatric acute myeloid leukemia (AML) patients who would benefit most from gemtuzumab ozogamicin (GO) therapy. <b>Methods:</b> Within the framework of the phase Ⅲ AAML0531 rand...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2025-03-01
|
| Col·lecció: | Bioengineering |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2306-5354/12/3/297 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|